BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Th...
Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present.
As we enter the final three months of 2025, some investors may be looking for red-hot growth stocks with room to run. Whereas others may be searching for beaten-down stocks at compelling valuations to boost their passive income.
Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three key drugs, Trikafta, Kaftrio, and Alyftrek, which are part of the CF portfolio, reached about $2.71 billion in the second quarter of 2025, up 10.6% year-on-year. On the positive side, Vertex's oper...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD). These updates represent significant progress toward reaching the Company's goal of bringing forward first-in-class or b...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults and the first new class of pain medicine approved in more than 20 years. During the 202...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.